Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
- Revenue in USD (TTM)0.00
- Net income in USD-7.82m
- Incorporated2009
- Employees17.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 17.26m | 3.00 | -- | 5,002.13 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 17.45m | 4.00 | -- | 302.69 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 17.71m | 2.00 | -- | 2.25 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 18.61m | 26.00 | -- | 2.05 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 18.80m | 4.00 | -- | 0.4964 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 18.88m | 12.00 | -- | -- | -- | 145.20 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Edesa Biotech Inc | 0.00 | -7.82m | 19.03m | 17.00 | -- | 4.08 | -- | -- | -1.15 | -1.15 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -82.82 | -103.16 | -96.38 | -123.95 | -- | -- | -- | -- | -- | -181.61 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 19.21m | 5.00 | -- | 2.06 | -- | -- | -15.95 | -15.95 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 19.25m | 17.00 | -- | 7.49 | -- | 4.59 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 19.93m | 1.00 | -- | 0.6669 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 20.08m | 4.00 | -- | 6.47 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Vyne Therapeutics Inc | 570.00k | -26.74m | 20.16m | 10.00 | -- | 0.7261 | -- | 35.37 | -0.6253 | -0.6194 | 0.0133 | 0.8332 | 0.0117 | -- | -- | 57,000.00 | -55.09 | -51.61 | -66.96 | -63.41 | -- | -- | -4,690.53 | -5,944.47 | -- | -- | 0.00 | -- | 13.77 | -51.39 | 32.84 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 20.34m | 6.00 | -- | -- | -- | 58.05 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Purminds Enterprises Inc | 0.00 | -77.46k | 20.66m | 0.00 | -- | 0.042 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 20.77m | 66.00 | -- | -- | -- | 2.22 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
Data as of Mar 03 2026. Currency figures normalised to Edesa Biotech Inc's reporting currency: US Dollar USD
36.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Dec 2025 | 687.50k | 8.25% |
| Velan Capital Investment Management LPas of 31 Dec 2025 | 687.50k | 8.25% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 687.50k | 8.25% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 625.00k | 7.50% |
| DRW Securities LLCas of 31 Dec 2025 | 134.22k | 1.61% |
| Diadema Partners LPas of 31 Dec 2025 | 54.03k | 0.65% |
| Citadel Securities LLCas of 31 Dec 2025 | 53.63k | 0.64% |
| Geode Capital Management LLCas of 31 Dec 2025 | 46.54k | 0.56% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 37.14k | 0.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 18.68k | 0.22% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
